Stockscreener 앱 받기
0.76
1.53%
-0.0118
시간 외 거래:
.76
전일 마감가:
$0.7718
열려 있는:
$0.8
하루 거래량:
99,503
Relative Volume:
0.39
시가총액:
$57.78M
수익:
$1.29M
순이익/손실:
$-29.87M
주가수익비율:
-2.1111
EPS:
-0.36
순현금흐름:
$-14.70M
1주 성능:
+13.23%
1개월 성능:
+47.43%
6개월 성능:
+17.28%
1년 성능:
+14.27%
1일 변동 폭
$0.7214
$0.80
1주일 범위
$0.66
$0.94
52주 변동 폭
$0.3951
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
VNRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.76 | 57.78M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
410.65 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
201.00 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
530.40 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
118.62 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.71 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock By Investing.com - Investing.com India
VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock - Investing.com
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure - MarketScreener
VolitionRx (NYSE:VNRX) Rating Increased to Strong-Buy at Jones Trading - Defense World
VolitionRX (VNRX) Coverage Initiated with a 'Buy' Rating by Jones Trading | VNRX Stock News - GuruFocus
JonesTrading Initiates Coverage on VolitionRx Limited With Buy Rating, $3 Price Target - marketscreener.com
Jones Trading initiates VolitionRX with Buy, sets $3 target By Investing.com - Investing.com India
VolitionRx (VNRX) Receives Buy Rating with Promising Price Targe - GuruFocus
VolitionRx initiated with a Buy at JonesResearch - TipRanks
VolitionRx (VNRX) Receives Buy Rating with Promising Price Target | VNRX Stock News - GuruFocus
Director Makes Bold Move with Major VolitionRX Stock Purchase - TipRanks
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties - Yahoo Finance
VolitionRx director Guy Innes buys $10,772 in common stock By Investing.com - Investing.com South Africa
VolitionRx director Guy Innes buys $10,772 in common stock - Investing.com
VNRX: Management's key financial goal for 2025 is to be cash neutral on a full year basis. - Research Tree
VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applicati - Yahoo Finance
VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd. Earnings Call Reveals Promising Growth - TipRanks
VolitionRX shares hold as Benchmark maintains rating - Investing.com Australia
VNRX stock touches 52-week low at $0.42 amid market challenges - Investing.com Canada
VolitionRX shares hold as Benchmark maintains rating By Investing.com - Investing.com India
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats - Yahoo Finance
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats By Investing.com - Investing.com Canada
VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones - Yahoo Finance
VolitionRx Reports Strong Q1 2025 Performance - TipRanks
VolitionRX (VNRX) Sees Revenue Growth and Cost Reduction in Q1 2 - GuruFocus
Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast By Investing.com - Investing.com Nigeria
Transcript : VolitionRx Limited, Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com
Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast - Investing.com
Volitionrx Ltd earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
VolitionRX: Q1 Earnings Snapshot - CT Insider
VolitionRx Q1 2025 Earnings Call Transcript - MarketBeat
Volitionrx Ltd earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa
VolitionRx reports Q1 revenue $0.25M, consensus $1.08M - TipRanks
Volition (VNRX) Targets Diagnostic Market Expansion with Nu.Q Platform | VNRX Stock News - GuruFocus
VolitionRX Ltd Reports Q1 2025 Revenue of $0.25 Million, Missing - GuruFocus
VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update - Yahoo Finance
VolitionRx (VNRX) Expected to Announce Quarterly Earnings on Monday - Defense World
VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock - Barchart.com
VolitionRx Updates Progress Of Nu.Q NETs Test Adoption - marketscreener.com
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption - Yahoo Finance
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
VolitionRx enters new sales agreement, terminates old one - Investing.com Australia
VolitionRx enters new sales agreement, terminates old one By Investing.com - Investing.com South Africa
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
VolitionRX Ltd 주식 (VNRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Innes Guy Archibald | Director |
Jun 03 '25 |
Buy |
0.54 |
20,000 |
10,772 |
888,689 |
| Micallef Jacob Vincent | Chief Scientific Officer |
May 19 '25 |
Buy |
0.43 |
50,000 |
21,500 |
426,033 |
| Reynolds Cameron John | President and CEO |
May 19 '25 |
Buy |
0.44 |
20,000 |
8,730 |
2,319,222 |
| Reynolds Cameron John | President and CEO |
Mar 26 '25 |
Buy |
0.55 |
181,818 |
100,000 |
2,299,222 |
| Innes Guy Archibald | Director |
Mar 26 '25 |
Buy |
0.55 |
181,818 |
100,000 |
868,689 |
| Innes Guy Archibald | Director |
Dec 09 '24 |
Buy |
0.57 |
174,764 |
100,000 |
617,085 |
| STILL TIMOTHY I | Director |
Dec 09 '24 |
Buy |
0.57 |
87,382 |
50,000 |
1,487,382 |
| Micallef Jacob Vincent | Chief Scientific Officer |
Dec 09 '24 |
Buy |
0.57 |
43,691 |
25,000 |
394,352 |
| Reynolds Cameron John | President and CEO |
Dec 09 '24 |
Buy |
0.57 |
139,811 |
80,000 |
2,117,404 |
| Innes Guy Archibald | Director |
Aug 20 '24 |
Buy |
0.67 |
150,000 |
100,500 |
406,683 |
0.69%
0.93%
자본화:
|
볼륨(24시간):